ImmunoGen, Inc. Form 8-K
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d)
OF
THE SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): January 27, 2006
ImmunoGen,
Inc.
(Exact
name of registrant as specified in its charter)
| |
Massachusetts
|
0-17999
|
04-2726691
|
|
| |
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
128
Sidney Street, Cambridge, MA 02139
(Address
of principal executive offices) (Zip Code)
Registrant's
telephone number, including area code: (617) 995-2500
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see
General
Instruction A.2. below):
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
8.01 - OTHER EVENTS
On
January 31, 2006, ImmunoGen,
Inc. (Nasdaq: IMGN) issued a press release to announce that the Company has
been
informed by Genentech (NYSE: DNA) that the trastuzumab-DM1 Investigational
New Drug (IND) application submitted by Genentech to the U.S. Food and Drug
Administration (FDA) has become effective. This event triggers a $2 million
milestone payment to ImmunoGen. Trastuzumab-DM1 comprises ImmunoGen's
cell-killing agent, DM1, linked to Genentech’s therapeutic antibody,
trastuzumab, which targets overexpression of the HER2 protein. HER2
overexpression is associated with approximately 20 percent of all breast
cancers. This milestone was earned under a May 2000 agreement whereby Genentech
has an exclusive license to use ImmunoGen's maytansinoid TAP technology
with therapeutic antibodies to HER2, including trastuzumab.
A
copy of
the press release is attached to this current report on Form 8-K as Exhibit
99.1.
ITEM
9.01. FINANCIAL STATEMENTS AND EXHIBITS
|
Exhibit
No.
|
|
Exhibit
|
| |
|
|
|
99.1
|
|
Press
Release of ImmunoGen, Inc. dated January 31,
2006
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
ImmunoGen,
Inc.
|
| |
(Registrant)
|
| |
|
|
Date:
January 31, 2006
|
/s/
Karleen M. Oberton
|
| |
|
| |
Karleen
M. Oberton
|
| |
Senior
Corporate Controller
|
| |
(Principal
Accounting Officer)
|